Dovato is owned by Viiv Hlthcare.
Dovato contains Dolutegravir Sodium; Lamivudine.
Dovato has a total of 3 drug patents out of which 0 drug patents have expired.
Dovato was authorised for market use on 08 April, 2019.
Dovato is available in tablet;oral dosage forms.
Dovato can be used as treatment of hiv infection.
The generics of Dovato are possible to be released after 24 January, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8129385||VIIV HLTHCARE||Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness|| |
(4 years from now)
|US9242986||VIIV HLTHCARE||Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates|| |
(6 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11234985||VIIV HLTHCARE||Antiviral therapy|| |
(7 years from now)
|New Combination (NC)||Apr 8, 2022|
|New Indication (I)||Aug 6, 2023|
Market Authorisation Date: 08 April, 2019
Treatment: Treatment of hiv infection
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic